RP182 Compositions and Methods

By inducing conformational changes through reagents bound to the sugar recognition domain of CD206, the problem of difficulty in targeting CD206 and regulating macrophage activity in the prior art is solved, and the activation of tumor-associated macrophages and M2 macrophages are achieved. Reduce, enhancing the phagocytosis of tumor cells.

CN112840211BActive Publication Date: 2024-11-12NANTES BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980056593.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-08-27
Filing Date
2019-08-26
Publication Date
2024-11-12
Estimated Expiration
2039-08-26

AI Technical Summary

Technical Problem

The prior art is difficult to selectively target the CD206 receptor, regulate macrophage activity, especially in the tumor environment to activate tumor-associated macrophages and reduce M2 macrophages.

Method used

Induce CD206 conformational changes, activate phagocytosis of tumor-associated macrophages or induce M2 macrophage death by reagents that bind to CD206's sugar recognition domain 4 (CRD4) and sugar recognition domain 5 (CRD5) Such as RP182 and its derivatives are used as pharmaceutical reagents.

Benefits of technology

The specific targeting of CD206 was achieved, which significantly activates the phagocytosis of tumor-associated macrophages, reduces immunosuppressive M2 macrophages, transforms the M1/M2 macrophage population into M1 type, and enhances the phagocytosis ability of tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112840211B_ABST
    Figure CN112840211B_ABST
Patent Text Reader

Abstract

Compositions and methods for domain-specific targeting of CD206 are presented, wherein selected agents bind to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206. In certain aspects of the inventive subject matter, the binding is specific, causes a conformational change in CD206, and induces phagocytosis of tumor-associated macrophages and / or death of M2 macrophages.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to our co-pending U.S. provisional patent application serial number 62 / 723,411 filed on August 27, 2018, and is incorporated herein by reference.

[0002] Sequence Listing

[0003] The contents of an ASCII text file of a sequence listing named 102719.0019PCT_ST25, 7 kb in size, was created on August 23, 2019 and was submitted electronically with this application via EFS-Web, the contents of which are incorporated by reference in their entirety. Technical Field

[0004] The technical field of the present invention is compositions and methods for targeting CD206, and more particularly relates to the identification and use of compounds that activate tumor-associated macrophages and reduce or eliminate M2 macrophages. Background Art

[0005] The Background Description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is it an admission that any publication explicitly or implicitly referenced is prior art.

[0006] All publications and patent applications are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.

[0007] CD206 (mannose receptor) is a complex receptor that is commonly found on the surface of macrophages and is thought to recognize mannose, N-acetylglucosamine, and fucose, which are commonly found in glycoproteins of various microorganisms. Therefore, CD206 appears to play a role in the innate immune response. However, selective agents that modulate macrophage activity remain elusive, in part due to the complex structure of CD206. Therefore, there remains a need for compositions and methods that selectively target CD206. Summary of the invention

[0008] Disclosed herein are various compositions and methods for domain-specific targeting of CD206, wherein selected agents bind to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206. Such binding is specific, causes conformational changes in CD206, and induces phagocytosis of tumor-associated macrophages and / or death of M2 macrophages.

[0009] In one aspect of the inventive subject matter, the inventors contemplate a method for screening a pharmaceutical agent, comprising the steps of modeling or identifying an agent that is a selective binder to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206; the step of quantifying the affinity of the agent for the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206; and after confirming that the agent binds to CRD4 and CRD5, the step of using the agent in a pharmaceutical formulation.

[0010] In some embodiments, the contemplated method further comprises the step of using a molecular model of CD206 in the modeling or identification step, further comprising the step of identifying conformational changes of CD206 after binding the agent, further comprising the step of binding the agent to macrophages in vitro, further comprising the step of testing the agent in vitro for induction of phagocytic activity, and / or further comprising the step of testing in vitro for induction of apoptosis of M2 macrophages. Most typically, the agent is RP182, a derivative of RP182, or an analog of RP182 (e.g., a bacterial virulence protein or an analog thereof, a collagen variant, or an analog thereof). It is also contemplated that the pharmaceutical formulation is an anticancer formulation.

[0011] Thus, the inventors contemplate (1) using an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 to induce a conformational change in CD206, (2) using an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 to activate phagocytosis of tumor-associated macrophages, (3) using an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 to induce M2 macrophage cell death or convert an M1 / M2 macrophage population into an M2 macrophage content-depleted population, and (4) using an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 to identify cells expressing CD206, wherein the agent is coupled to a detectable label.

[0012] From a different perspective, the inventors contemplate a method of inducing death of M2 macrophages, comprising the step of contacting the M2 macrophages with a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in an amount effective to induce death of the M2 macrophages.

[0013] Alternatively, the inventors contemplate a method of converting a population of M1 / M2 macrophages into a population depleted of M2 macrophage content, comprising the step of contacting the population of M1 / M2 macrophages with a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in an amount effective to convert the population of M1 / M2 macrophages into a population depleted of M2 macrophage content.

[0014] In addition, the inventors also contemplate a method for activating phagocytosis of tumor-associated macrophages, comprising the step of contacting the tumor-associated macrophages with a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in an amount effective to activate phagocytosis of tumor-associated macrophages.

[0015] For example, in such methods, the compound is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof, and / or the contacting step is performed in vivo.

[0016] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments and the accompanying drawings, in which like reference numerals represent like components. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Exemplary results are shown for binding of RP182 to CD206 (relative to control peptide RP426).

[0018] Figure 2 Exemplary results are shown for specific target binding of PBS versus RP-182 over the indicated temperature range.

[0019] Figure 3 The structural similarities of RP peptides to microbial cell surface proteins are depicted.

[0020] Figure 4 An exemplary illustration of the design process of CD206 ligands is depicted.

[0021] Figure 5 Native proteins implicated in immune system activation or macrophage clearance are depicted for comparison with RP182 and control peptides.

[0022] Figure 6 Depicted are exemplary results demonstrating that RP182 displays higher affinity for the C-type lectin domain compared to the native ligand.

[0023] Figure 7 Depicted are exemplary results leading to the in silico identification of the mannose receptor CD206 as a specific C-type lectin receptor target for RP182.

[0024] Figure 8 Depicted are exemplary data where RP182 has a higher affinity for CD206 than any of the native peptides evaluated.

[0025] Fig. 9 Many possible structural models for CD206 were depicted, and the best-fit model was derived to fit the small-angle X-ray data.

[0026] Fig.10 It is to establish a molecular model of the topological structure and key domain / amino acid positions of CD206.

[0027] Fig.11 Identification of specific domains targeted by RP peptides is shown.

[0028] Fig.12 Predicted conformational changes of RP182 docking and CD206 receptor are shown.

[0029] Fig.13 The results of electron microscopy to verify the conformational changes under RP182 treatment are depicted.

[0030] Fig.14 Results of % binding of RP182 (20 μM) on CD206+ / CD11b+ cells are depicted.

[0031] Fig.15 Depicted are results showing that RP182 stimulates phagocytic activity.

[0032] Fig.16 Depicted are results showing that RP182 stimulates phagocytosis of M2-like macrophages and TAMs.

[0033] Fig.17 Depicted are results showing phagocytosis of labeled KPC cells following RP182 treatment.

[0034] Fig.18 Results showing that the anti-M2 macrophage activity of RP-182 is CD206-dependent are depicted.

[0035] Fig.19 Shown is the measurement of autophagy and apoptosis of M2 macrophages induced by RP182 peptide in the presence of an autophagy inhibitor.

[0036] Fig. 20 is a graph of the dose response curve of RP-182 on the cell viability of murine M2 macrophages.

[0037] Fig.21 is a graph showing that RP182 treatment leads to decreased viability of M2 macrophages. DETAILED DESCRIPTION

[0038] The inventors have now discovered that natural antimicrobial peptides can be used as a starting point for identifying agents that selectively interact with CD206, particularly when computer simulation analysis of candidate compounds is used in conjunction with a CD206 model. Advantageously, molecules identified as selective binders of CD206, particularly the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CDD206, can be used as pharmaceutical agents that stimulate the phagocytic activity of tumor-associated macrophages and polarize the M1 / M2 macrophage population toward a population with reduced M2 content. It is apparent that such agents will advantageously activate phagocytosis of tumor cells while reducing immunosuppressive M2 macrophages. Notably, the inventors have discovered that at least some, if not all, of the agents that bind CRD4-5 will selectively bind to these domains and induce conformational changes in CD206, which may provide specific signals to macrophages.

[0039] For example, a kind of active compound (RP182) is derived from the natural antimicrobial peptide of the simulated microbial cell surface protein, and shows remarkable effect in activating immune cells by the transformation of macrophage group to activated / phagocytic M1 phenotype.Then, as shown in more detail below, other synthetic analogs are engineered, and the induction of CD206 binding, conformational changes and the biological effect to various cell groups (particularly macrophages) are screened.In their research process, the inventors found that the target receptor of this class of compounds is CD206.In confirmatory experiments, RP182 is proved to have an affinity far higher than various natural ligands.In addition, the use of the novel 3D modeling of CD206 allows identification of specific target domains, and predicts conformational changes (verified by experiments, as shown in more detail below).

[0040] It is readily appreciated that agents that bind to CD206, particularly carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5), are particularly useful in the manufacture of pharmaceutical compositions that can immunostimulate / activate tumor-associated macrophages and reduce the number of M2 macrophages with immunosuppressive functions in the tumor microenvironment.

[0041] Based on earlier considerations (not shown), the inventors first confirmed that RP182, a compound derived from a natural antimicrobial peptide, does bind to CD206. To this end, an SPR analysis was performed in which the binding of RP182 to CD206 was quantified. Figure 1 It can be seen that RP182 binds selectively and tightly to CD206, whereas the control peptide (RP426) binds with significantly lower affinity. Figure 2Depicted are the results of an additional confirmatory experiment in which a cellular thermal shift assay (CETSA) was performed to demonstrate target engagement. Here, a negative control (PBS) was compared to RP182 and the control peptide RP426. As can be seen, T agg The values ​​(mean and SD from two independent experiments performed in duplicate) clearly indicate a specific interaction with RP182 beyond the control.

[0042] To test the concept that various synthetic peptides would mimic antimicrobial peptides, structural modeling was performed and Figure 3 Provided in the exemplary results for comparison, wherein synthetic peptides are at the top and antimicrobial peptides are at the bottom. Computer simulation further evaluated other variants of a large number of peptide fragments, and selected peptides were screened for activity. It is noteworthy that in this process, it has been determined that reducing hydrophobicity by replacing alanine with other amino acids with other similar characteristics has produced a predicted increase in affinity for a variety of possible targets (initially including NFkB, TRAIL, CD206, etc.). When CD206 was determined as a target, ClusPro model was used to generate computer simulation calculations for predicted affinity (also referring to the figure generated using the 3D model of CD206 later). Figure 4 Selected peptides and calculated binding energies are depicted, along with structural predictions for these peptides. Figure 4 The synthetic sequences shown have the peptide sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5. Figure 5 Additional exemplary peptides of natural origin similar to RP182 are listed. Figure 5The sequences shown have peptide sequences according to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28. Thus, it should be understood that all of these peptide sequences and their analogs are considered suitable for use herein. For example, the host defense proteins most suitable for the immunomodulatory peptide structure / function paradigm domains are found at URL: aps.unmc.edu / AP / main.php utilizing Molly font. Provide a survey of this database, list 129 of 431 kinds of peptides, accounting for 29.93%, its domain is consistent with the structural determinant cluster required for activity. RP182 is optimized to have maximum amphipathicity, hydrophobicity and positive charge density, as shown in Molly font. RP426 is the control of testing hydrophobicity for the importance of activity. Molly font is described in: "Structure / Function Link Between Cytokine Domains and Natural and DesignedLytic Peptides:Medical Promise [Structure / Function Link Between Cytokine Domains and Natural and Designed Lytic Peptides:Medical Promise] (2012). "Jesse M.Jaynes and Gregory C.Bernard, in Small Wonders:Peptides for Disease Control [small miracle: peptides for disease control], 21-45, American Chemical Society [American Chemical Society], incorporated herein by reference. Peptides in the virulence and collagen fractions were then selected in a similar manner from proteins found in the protein database at URL: www.ncbi.nlm.nih.gov.

[0043] Seventeen different groups of human C-type lectins have been described, see "C-type lectins in immunity and homeostasis." Brown, GD et al. Nat Rev Immunol. 2018 Jun;18(6):374-389. A complete list of all known members can be found in the Animal Lectin Database at URL: www.imperial.ac.uk / research / animallectins / ctld / mammals / humanvmousedata.html. From this resource, 88 different C-type lectin human proteins were enumerated. Of these 88 proteins, 28 were selected for in silico studies because they had available crystal structures, as well as 3 different toll-like receptors. The crystal structures were investigated for binding to individual 10-mer sequences of the indicated biosimilars using ClusPro. Biosimilars were selected based on the sequence that was most similar to the 10-mer sequence in each class. Figure 6 The table on the left shows the results, sorted first by group and second by the average of the normalized cluster binding energy (NCBE). The three lowest binding energies (in kcal / mol) for each receptor / ligand combination are shown. The first section compares the computer simulated binding of all peptides to the 28 selected human C-type lectins described in the publication. The additional columns show the results, sorted first by the group with the listed -BE and second by the average of the normalized cluster binding energy (NCBE).

[0044] Then, using ClusPro, the crystal structures of 28 human C-type lectins and TLRs were investigated for binding to RP182. Figure 7 The two tables on the left show the results, sorted first by group and second by the average of the Normalized Cluster Binding Energy (NCBE). The top ten worst binding protein / ligand pairs are shown in the right panel.

[0045] Next, to confirm the selectivity of RP182 binding to MRC1 / CD206 compared to other biosimilars, the inventors repeated the above docking studies of biosimilars and RP182 using the SAXS-derived full-length CD206 structure. The last part of the data came from in silico measurements using the crystal structure PDB 5XTS described in "Structural Insights into the pH-Dependent Conformational Change and Collagen Recognition of the Human Mannose Receptor." Hu Z et al. Structure. 2018 Jan 2;26(1):60-71. The results are shown in Figure 2. Figure 8 As can be seen, the binding affinity of RP182 to full-length CD206 is also higher than that of any native peptide selected based on its relevance to immune activation or macrophage clearance.

[0046] In further work, various structural models for CD206 were developed and the best-fit model was derived to fit the small-angle X-ray data. Fig. 9 This model was then used in subsequent peptide design work as follows and is shown in Fig.10In. Here, human macrophage mannose receptor 1 protein (also known as MMR-1 or CD206) is a single-pass type I membrane signaling protein. The key topological features are a large extracellular region (1371aa), followed by a helical transmembrane (TM) domain and a relatively small cytoplasmic region (46aa). The protein sequence of human CD206 (1,456aa) was obtained from UniProt (UniProt ID P22897-1 NCBI ID: NP_002429.1) and contains two N-terminal domains (ricin-B type lectin and type II fibronectin), followed by eight C-type lectin domains (numbered 1 to 8), as well as a TM domain and a cytoplasmic domain. The 3D structural information of human CD206 is only available for a very small segment (644-787aa; C-type lectin 4 domain). In this work, the inventors constructed a complete 3D model of CD206 using one of the most reliable (CASP experimental based) methods advocated by the Iterative Threading and ASSEmblyRefinement software I-TASSER (Web server version; URL: zhanglab.ccmb.med.umich.edu / I-TASSER / for model building). I-TASSER uses a hierarchical approach that uses a multithreaded approach to extract the entire 3D model of CD206 from the RCSB-PDB ( www.rcsb.org ) identify 3D templates. Finally, a full-length model was constructed by iterative template fragment assembly simulation. In order to further help modeling, the inventors provide distance-restricted disulfide bond information identified using sequence similarity as distance-restricted input. The top thread templates identified by I-TASSER are 5ao5, 3jav, 5ao6 and 4igl. The normalized B factor values ​​(indicating the local accuracy of the model) of these models fluctuate near zero. In I-TASSER, model confidence is measured by C scores. The C score is between -5 and 2, and the higher the value, the higher the confidence. The first 4 models have the following C scores: -0.35, -1.93, -2.89 and -2.97.

[0047] The top 4 models were analyzed, and the top ranked I-TASSER model based on comparison of the small angle X-ray scattering model (SAXS; see A) and the I-TASSER confidence and C-score was determined to be the possible structural fold of CD206. The middle panel shows the I-TASSSER primary model in detail. The fibronectin type II domain appears to be partially embedded and surrounded by the c-terminal region of ricin and the C-type lectin-1 domain. The other C-type lectin domains appear to be tightly packed. The helical transmembrane domain is followed by two short helical regions of the cytoplasmic domain. The right panel is a surface model generated in Pymol.

[0048] The model thus obtained was then used to identify specific CD206 domains targeted by the RP peptides, such as Fig.11 It is worth noting that from Fig.12 As can be seen in Figure 1, the model predicts RP182 docking and conformational changes in the CD206 receptor. To confirm that the conformational changes are indeed not artifacts, the inventors used electron microscopy of CD206 in the presence and absence of RP182, with typical results as shown in Figure 1. Fig.13 shown.

[0049] Additional in vitro experiments demonstrated that ligand binding to carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) had various desired effects, including (a) strong and selective binding to CD206 (SPR, microscale thermophoresis, cellular thermal shift assay), (b) strong and selective binding to CD206+ cells, (c) induction of conformational changes in the CD206 molecule, (d) stimulation of phagocytic activity, and (e) reduction in M2 macrophages, as described below.

[0050] More specifically, Fig.14 Depicts FACS results of exemplary compound (RP182) binding to CD206+CD11b+ cells, while Fig.15 The results of selectively stimulating phagocytosis, autophagy and apoptosis of M2 polarized macrophages are depicted. As can be seen from the figure, after 2 hours of treatment with RP-182, RP-182 induced early and late phagocytosis without affecting CD206 levels. Immunofluorescence was performed on BMDM polarized to M1 and M2 and stained with anti-Rab5, etc., and RP182 (rather than control peptides RP-426 and MART-1) induced phagocytosis in M2 polarized macrophages. In addition, RP182 induced apoptosis (measured by caspase cleavage; left figure) and autophagy (measured by anti-LC-3; right figure), selectively killing mouse and human M2 polarized macrophages, but not repolarizing M2 to M1 macrophages. After treating M2 macrophages with RP-182, the production as a measure of M1 function increased.

[0051] Fig.16 Depicted are exemplary results showing that RP182 stimulates phagocytosis of M2-like macrophages and TAMs. Fig.17 In the figure, after RP182 treatment, the phagocytosis of the labeled KPC cells was significantly shown, and Fig.18 The results in show that the anti-M2 macrophage activity of RP-182 is CD206-dependent. Notably, even when autophagy was blocked, the apoptotic activity of RP182 treatment remained robust, suggesting that this activity is independent of signaling events such as internalization. Fig.19The results can be seen. Finally, Fig. 20 The dose-response curve of RP-182 on cell viability of murine M2 macrophages is shown, and Fig.21 These results indicate that RP182 treatment leads to decreased viability of M2 macrophages.

[0052] In some embodiments, the numbers representing the amount of components, characteristics (such as concentration), reaction conditions, etc., used to describe and claim certain embodiments of the present invention should be understood to be modified by the term "about" in some cases. Therefore, in some embodiments, the numerical parameters listed in the written specification and the appended claims are approximate values, which can vary according to the desired characteristics that a particular embodiment attempts to obtain. In some embodiments, the numerical parameters should be interpreted according to the number of reported significant figures and by applying ordinary rounding techniques. Although the numerical ranges and parameters of the wide range of some embodiments of the present invention are approximate values, the numerical values ​​set forth in the specific examples are reported as accurately as practicable. The numerical values ​​presented in some embodiments of the present invention may contain certain errors caused by the standard deviation found in their respective test measurements. Unless the context indicates otherwise, all ranges listed herein should be interpreted as including their endpoints, and open ranges should be interpreted as including commercially practical values. Similarly, unless the context indicates otherwise, the list of all values ​​should be considered to include intermediate values.

[0053] As used in the specification herein and throughout the claims that follow, the meanings of "a", "an", and "the" include plural references unless the context clearly indicates otherwise. Also, as used in the specification herein, the meaning of "in" includes "in" and "on", unless the context clearly indicates otherwise. Also, and unless the context indicates otherwise, the term "coupled to" is intended to include direct coupling (where two elements coupled to each other are in contact with each other) and indirect coupling (where at least one additional element is located between the two elements). Thus, the terms "coupled to" and "coupled with" are used synonymously.

[0054] Furthermore, as used herein, the phrase "at least one of A and B" is intended to refer to 'A' and / or 'B', regardless of the nature of 'A' and 'B'. For example, in some embodiments, 'A' may be a single different species, while in other embodiments, 'A' may represent a single species within the genus referred to as 'A'. Likewise, in some embodiments, 'B' may be a single different species, while in other embodiments, 'B' may represent a single species within the genus referred to as 'B'.

[0055] It should be clear to those skilled in the art that, without departing from the inventive concept of this article, in addition to those already described, more modifications are possible. Therefore, the subject matter of the present invention is only limited to the scope of the appended claims. In addition, when interpreting the specification and claims, all terms should be interpreted in a manner as broad as possible consistent with the context. In particular, the term "comprises" and "comprising" should be interpreted as referring to elements, components or steps in a non-exclusive manner, thereby indicating that the mentioned elements, components or steps can exist, or use, or combine with other elements, components or steps not explicitly mentioned. In the case where the specification claims mention at least one of something selected from the group consisting of A, B, C ... and N, the text should be interpreted as requiring only one element in the group, rather than A plus N, or B plus N, etc.

Claims

1. A method for screening a pharmaceutical agent, the method comprising: Modeling or identifying agents that are selective binders to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206; quantifying the affinity of the reagent for the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206; as well as After confirming that the agent binds to the CRD4 and CRD5, the agent is used in a pharmaceutical formulation, wherein the agent is a RP182 derivative, an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

2. The method according to claim 1, further comprising the step of using a molecular model of CD206 in the modeling or identification step.

3. The method of claim 1, further comprising the step of identifying a conformational change of CD206 after binding of the agent.

4. The method according to claim 1, further comprising the step of combining the agent with macrophages in vitro.

5. The method according to claim 1, further comprising the step of testing the induction of phagocytic activity by the agent in vitro.

6. The method according to claim 1, further comprising the step of testing the induction of apoptosis of M2 macrophages in vitro.

7. The method of claim 1, wherein the pharmaceutical formulation is an anti-cancer formulation.

8. Use of an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 for inducing conformational changes in CD206, wherein the agent is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

9. Use of an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 in the manufacture of a medicament for activating the phagocytosis of tumor-associated macrophages, wherein the agent is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

10. Use of an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 in the manufacture of a medicament for inducing M2 macrophage death or converting an M1 / M2 macrophage population into an M2 macrophage content-depleted population, wherein the agent is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

11. Use of an agent that binds to the carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) of CD206 for identifying cells expressing CD206, wherein the agent is coupled to a detectable label, wherein the agent is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

12. Use of a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in the manufacture of a medicament for use in a method for inducing death of M2 macrophages, the method comprising: The M2 macrophages are contacted with a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in an amount effective to induce death of the M2 macrophages, wherein the compound is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

13. Use of a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in the manufacture of a medicament for use in a method for converting an M1 / M2 macrophage population into an M2 macrophage content-depleted population, the method comprising: The M1 / M2 macrophage population is contacted with a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in an amount effective to convert the M1 / M2 macrophage population into a population depleted of M2 macrophage content, wherein the compound is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

14. Use of a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in the manufacture of a medicament for use in a method for activating phagocytosis of tumor-associated macrophages, the method comprising: The tumor-associated macrophages are contacted with a compound targeting carbohydrate recognition domain 4 (CRD4) and carbohydrate recognition domain 5 (CRD5) in an amount effective to activate phagocytosis of the tumor-associated macrophages, wherein the compound is an RP182 analog, a bacterial virulence protein or an analog thereof, or a collagen variant or an analog thereof.

15. The use according to any one of claims 12-14, wherein the contacting step is performed in vivo.